Article
The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.
The Journal of thoracic and cardiovascular surgery - 1 Apr 1999
Kandioler-Eckersberger D, Kappel S, Mittlböck M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, Eckersberger F
Abstract excerpt
BACKGROUND: The cytotoxic effects of cisplatin and anthracyclins have been attributed to apoptosis induction, which has been recognized as a major function of the TP53 gene. The TP53 gene appears to be mutated in about 50% of cases of non-small cell lung cancer. A possible dependence of chemotherapy response on TP53 genotype was evaluated retrospectively in a group of patients with advanced non-small cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.